Evidence map›Paper›PMID 26151456›Full record

SynthesisBritish journal of cancer2015

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.

C M Nagle, S C Dixon, A Jensen, S K Kjaer, F Modugno, A deFazio, S Fereday, J Hung, S E Johnatty, Australian Ovarian Cancer Study Group and 49 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2020
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Weight Loss Randomized Intervention Trials in Female Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Pooled it
  6. Effect of exercise on body composition among women with ovarian cancer.Journal of cancer survivorship : research and practice · 2023
    Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors.

C M NaglePopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
S C DixonPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
A JensenVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
S K KjaerVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
F ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pennsylvania, PA, USA.
A deFazioDepartment of Gynaecological Oncology, Westmead Hospital, Westmead, NSW, Australia.
S FeredayPeter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
J HungDepartment of Gynaecological Oncology, Westmead Hospital, Westmead, NSW, Australia.
S E JohnattyGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Australian Ovarian Cancer Study Group
P A FaschingDavid Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
M W BeckmannDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
D LambrechtsVesalius Research Center, VIB, Leuven, Belgium.
I VergoteDepartment of Obstetrics and Gynecology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
E Van NieuwenhuysenDepartment of Obstetrics and Gynecology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
S LambrechtsDepartment of Obstetrics and Gynecology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
H A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
M A RossingProgram in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
J A DohertyDepartment of Community and Family Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
K G WicklundProgram in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
J Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
M T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
R B NessSchool of Public Health, University of Texas, Houston, TX, USA.
K MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
F HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
A du BoisDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
P HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
I SchwaabInstitut für Humangenetik Wiesbaden, Wiesbaden, Germany.
K MatsuoDepartment of Preventive Medicine, Faculty of Medical Sciences, Kyushu University, Nagoya, Aichi, Japan.
S HosonoDivision of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
E L GoodeDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
R A VierkantDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
M C LarsonDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
B L FridleyDepartment of Biostatistics, University of Kansas, Kansas City, KS, USA.
C HøgdallDepartment of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
J M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
R P WeberDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
D W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
K L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
E V BanderaRutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
L PaddockNew Jersey State Cancer Registry, Trenton, NJ, USA.
L Rodriguez-RodriguezRutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
N WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
H P YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
L A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J LissowskaDepartment of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center, Warsaw, Poland.
E HøgdallVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
L LundvallDepartment of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
A WhittemoreDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
V McGuireDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
W SiehDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
J RothsteinDepartment of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
R SutphenEpidemiology Center, College of Medicine, University of South Florida, Tampa, FL, USA.
H Anton-CulverDepartment of Epidemiology, School of Medicine, University of California Irvine, Irvine, California, USA.
A ZiogasDepartment of Epidemiology, School of Medicine, University of California Irvine, Irvine, California, USA.
C L PearceKeck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
A H WuKeck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
P M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Ovarian Cancer Association Consortium

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1985 to 2009
$18.2M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
NCI NIH HHS K07 CA080668NCI NIH HHS K07-CA080668NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07-CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K07-CA143047NCI NIH HHS K22 CA138563NCI NIH HHS K22-CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01-CN-55424NCI NIH HHS N01-PC-67001NCI NIH HHS P01 CA017054NCI NIH HHS P01-CA17054NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA072720NCI NIH HHS P30-CA072720NCI NIH HHS P30-CA15083NCI NIH HHS P50 CA105009NCI NIH HHS P50-CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NCI NIH HHS P50 CA159981NCI NIH HHS P50-CA159981NCI NIH HHS R01-CA016056NCI NIH HHS R01 CA054419NCI NIH HHS R01-CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01-CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01CA058860NCI NIH HHS R01 CA074850NCI NIH HHS R01-CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01-CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01-CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01-CA087538NCI NIH HHS R01 CA092044NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA106414NCI NIH HHS R01-CA106414NCI NIH HHS R01 CA112523NCI NIH HHS R01-CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01-CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01-CA126841NCI NIH HHS R01-CA61107NCI NIH HHS R01-CA83918NCI NIH HHS R01-CA95023NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R03-CA115195NCI NIH HHS U01 CA069417NCI NIH HHS U01-CA69417NCI NIH HHS U01-CA71966NCRR NIH HHS M01 RR000056NCRR NIH HHS MO1-RR000056
6 · The paper itself

Abstract

backgroundObservational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with survival and whether this association varies for the different histologic subtypes are not clear. We undertook an international collaborative analysis to assess the association between body mass index (BMI), assessed shortly before diagnosis, progression-free survival (PFS), ovarian cancer-specific survival and overall survival (OS) among women with invasive ovarian cancer.

methodsWe used original data from 21 studies, which included 12 390 women with ovarian carcinoma. We combined study-specific adjusted hazard ratios (HRs) using random-effects models to estimate pooled HRs (pHR). We further explored associations by histologic subtype.

resultsOverall, 6715 (54%) deaths occurred during follow-up. A significant OS disadvantage was observed for women who were obese (BMI: 30-34.9, pHR: 1.10 (95% confidence intervals (CIs): 0.99-1.23); BMI: ⩾35, pHR: 1.12 (95% CI: 1.01-1.25)). Results were similar for PFS and ovarian cancer-specific survival. In analyses stratified by histologic subtype, associations were strongest for women with low-grade serous (pHR: 1.12 per 5 kg m(-2)) and endometrioid subtypes (pHR: 1.08 per 5 kg m(-2)), and more modest for the high-grade serous (pHR: 1.04 per 5 kg m(-2)) subtype, but only the association with high-grade serous cancers was significant.

conclusionsHigher BMI is associated with adverse survival among the majority of women with ovarian cancer.

Indexed as

Body Mass IndexCarcinoma, Ovarian EpithelialDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateNeoplasms, Glandular and EpithelialObesityOvarian Neoplasms

Identifiers

PMID26151456
PMCPMC4559823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.